Lepu Medical Technology (Beijing) Co., Ltd. Stock

Equities

300003

CNE100000H44

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-20 pm EDT 5-day change 1st Jan Change
16.06 CNY +0.12% Intraday chart for Lepu Medical Technology (Beijing) Co., Ltd. -2.37% -0.62%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * 8.89B 1.23B Sales 2025 * 10.13B 1.4B Capitalization 29.83B 4.12B
Net income 2024 * 1.98B 274M Net income 2025 * 2.28B 315M EV / Sales 2024 * 2.93 x
Net cash position 2024 * 3.75B 519M Net cash position 2025 * 4.57B 631M EV / Sales 2025 * 2.49 x
P/E ratio 2024 *
15.1 x
P/E ratio 2025 *
13.2 x
Employees -
Yield 2024 *
2.19%
Yield 2025 *
2.3%
Free-Float 62.68%
More Fundamentals * Assessed data
Dynamic Chart
Beijing Yuding Additive Manufacturing Research Institute Co., Ltd. announced that it has received funding from CGII Private Fund Co., Ltd, Xi'an CAS Star Technology Incubator Co., Ltd., SDIC Unity Capital Co., Ltd., Lepu Medical Technology Co., Ltd., China Xiong'an Group Fund Management Co., Ltd. CI
Lepu Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Lepu Medical Technology Co., Ltd.'s Equity Buyback Plan announced on October 25, 2023. CI
CNNC SUFA Technology Chairman Steps Down; Successor Named MT
Lepu Biopharma Shareholders to Vote Jan. 31 on Contract to Produce Drugs for Lepu Medical Technology MT
Tranche Update on Lepu Medical Technology Co., Ltd.'s Equity Buyback Plan announced on October 25, 2023. CI
PW Medtech Renews Purchase Deal with Lepu Medical MT
PW Medtech Group Limited Enters into the Renewed Purchase of Medical Devices Molds and Components Framework Agreement with Lepu Medical CI
Lepu Biopharma Renews Procurement Agreement With Lepu Medical Technology MT
Lepu Biopharma to Provide Drug Production Services to Lepu Medical Technology MT
Lepu Medical Technology Co., Ltd. announces an Equity Buyback for CNY 500 million worth of its shares. CI
Lepu Medical Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Lepu Medical Technology Co., Ltd. authorizes a Buyback Plan. CI
Lepu Medical Technology's Unit Gets Nod for Medical Device MT
Chinese Warehousing Sector Grows in Seventh Straight Month MT
More news
1 day+0.12%
1 week-2.37%
Current month+8.88%
1 month+20.66%
3 months+9.62%
6 months-6.52%
Current year-0.62%
More quotes
1 week
15.74
Extreme 15.74
16.52
1 month
13.67
Extreme 13.67
16.63
Current year
11.60
Extreme 11.6
16.63
1 year
11.60
Extreme 11.6
25.26
3 years
11.60
Extreme 11.6
35.62
5 years
11.60
Extreme 11.6
46.96
10 years
8.95
Extreme 8.95
46.96
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 21-04-25
Director of Finance/CFO 51 07-02-28
Chairman 61 -
Members of the board TitleAgeSince
Chairman 61 -
Director/Board Member 57 13-12-31
Director/Board Member 57 20-01-21
More insiders
Date Price Change Volume
24-05-21 16.06 +0.12% 14,809,620
24-05-20 16.04 +0.69% 16,283,390
24-05-17 15.93 -0.75% 17,634,630
24-05-16 16.05 -0.56% 29,936,090
24-05-15 16.14 -1.88% 26,753,820

End-of-day quote Shenzhen S.E., May 20, 2024

More quotes
Lepu Medical Technology (Beijing) Co., Ltd. specialized in the design, manufacture and marketing of medical devices and equipment. The group is also involved in the development and manufacturing of active pharmaceutical ingredients. Net sales break down by activity as follows: - sale of medical devices and instruments (57.9%): primarily for cardiovascular interventions, cardiac surgery, cardiac rhythm management, anesthesia, intensive care, in vitro diagnostics and general surgery; - sale of active pharmaceutical ingredients (30.6%): for the manufacturing of pharmaceutical products in the fields of cardiovascular diseases, infectious diseases, oncology, central nervous system disorders, etc.; - sale of digital health and hospital network management solutions (11.6%). China accounts for 64.7% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
16.06 CNY
Average target price
20.69 CNY
Spread / Average Target
+28.83%
Consensus
  1. Stock Market
  2. Equities
  3. 300003 Stock
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW